+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ADC Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Antibody Isotype, Type of Payload, Type of Linker, and Key Geographical Regions

  • PDF Icon

    Report

  • 510 Pages
  • May 2024
  • Region: Global
  • Roots Analysis
  • ID: 5215168

Surging Demand for Antibody Drug Conjugates Driving the ADC Contract Manufacturing Market

The global ADC contract manufacturing market is estimated to be worth $1.79 billion in 2024 and is expected to grow at a CAGR of 13% during the forecast period, reaching ~$6.87 billion by 2035. The study consists of industry trends, detailed market analysis, service provider landscape, competitiveness landscape, recent expansions, partnerships and collaborations, capacity analysis, clinical trial analysis, likely partner analysis, demand analysis, value chain analysis, market impact analysis, and market forecast and opportunity analysis. The growth in the ADC contract manufacturing market size over the next decade is likely to be the result of anticipated increase in demand for antibody drug conjugates.

In recent years, antibody drug conjugates (ADC) have emerged as a potent class of therapeutics targeting a wide range of cancers including solid tumors and hematological tumors. These complex molecules consist of an antibody, which is attached to biologically active, cytotoxic agents through chemical linkers. ADC therapeutics possess enhanced stability, target specificity, tumor selectivity and pharmacokinetic properties. These properties have supported extensive research and development initiatives being undertaken for the advancement of ADC therapies to the market. In this context, the current ADC pipeline features the presence of over 260 candidates being evaluated in clinical trials, along with 23 ADC therapeutic programs that have already been approved by various regulatory agencies. The potential of such therapies in selectively targeting tumor cells, while limiting off target toxicities have paved the way for their success and widespread application in the healthcare industry.

However, the ADC manufacturing process is highly complex and is fraught with several challenges, including drug / linker side reactions, exposure to toxicity, contamination and up-scaling. Additionally, the manufacturing process requires significant expertise and use of cutting-edge technologies, which are highly cost intensive. Therefore, the ADC developers prefer outsourcing the manufacturing operations to ADC contract manufacturers. With an intent of cost saving, ADC therapy developers are continually utilizing the experience, capabilities and manufacturing facilities available with the contract manufacturing organizations in order to support their manufacturing operations. Further, it is worth mentioning that the CMOs engaged in ADC contract manufacturing are actively undertaking initiatives to become one-stop shops and mitigate the challenges associated with technology transfer and scale-up. Considering the increasing demand for ADCs and the increasing preference for outsourcing operations by drug developers, the ADC contract manufacturing market is likely to witness substantial market growth during the forecast period.

ADC Contract Manufacturing Market Share Insights

The market research report presents an in-depth analysis of the various companies that are engaged in the global ADC contract manufacturing market, across different segments, as defined below:

  • Historical Trend: 2019-2021
  • Base Year: 2022-2023
  • Forecast Period: 2024-2035
  • Market Size in 2024: $1.79 Billion
  • CAGR: 13%
  • Stage of Development
    • Phase I
    • Phase II
    • Phase III
  • Commercial
  • Process Component
    • Antibody
    • HPAPI / Cytotoxic Payload
    • Conjugation / Linker
    • Fill / Finish
  • Target Indication
    • Solid Tumors
    • Hematological Tumors
    • Others
  • Antibody Generation
    • Second Generation
    • Third Generation
    • Fourth Generation
    • Next Generation
  • Antibody Origin
    • Humanized
    • Chimeric
    • Murine
    • Others
  • Antibody Isotype
    • IgG1
    • IgG4
    • Others
  • Type of Payload
    • Auristatin
    • Camptothecin
    • DNA Topoisomerase I Inhibitor
    • Maytansinoid
    • Others
  • Type of Linker
    • Maleimide
    • SMCC
    • Tetrapeptide-based linker
    • Valine-citrulline
    • Others
  • Key Geographical Regions
    • North America
    • Europe
    • Asia-Pacific and Rest of the World
  • Key Companies Profiled
    • AbbVie Contract Manufacturing
    • Abzena
    • CARBOGEN AMCIS
    • Catalent Pharma Solutions
    • Cerbios-Pharma
    • Formosa Laboratories
    • GBI
    • Lonza
    • MabPlex
    • Millipore Sigma
    • Piramal Pharma Solutions
    • Sterling Pharma Solutions
    • WuXi Biologics
    • (Full list of 30 companies captured is available in the report)
  • PowerPoint Presentation (Complimentary)
  • Customization Scope: 15% Free Customization
  • Excel Data Packs (Complimentary)
    • Market Landscape
    • Company Competitiveness Analysis
    • Recent Expansions
    • Partnerships and Collaborations
    • Capacity Analysis
    • Clinical Trial Analysis
    • Likely Partner Analysis
    • Demand Analysis
    • Market Forecast and Opportunity Analysis

ADC Contract Manufacturing Market Segmentation Overview

Market Share by Stage of Development

Based on the stage of development, the global ADC contract manufacturing market is categorized into phase I, phase II, phase III and commercial. The commercial segment occupies the highest share in 2023 and is expected to witness substantial growth in the coming years.

Market Share by Type of Component

Based on the type of component, the global antibody drug conjugates contract manufacturing market is categorized into antibody, HPAPI / cytotoxic payload, conjugation / linker and fill / finish. The antibody segment occupies the highest share in 2023 in the overall ADC contract manufacturing market and this trend is expected to remain same during the forecast period. This can be primarily attributed to the fact that antibody manufacturing is a time and cost-intensive process, owing to the complex cellular or protein engineering requirements.

Market Share by Target Indication

Based on the target indications, the global ADC contract manufacturing market is segmented into solid tumors, haematological tumors and others. With the anticipated approval of ADC therapeutics for their primary application in the treatment of solid tumors, this market segment is anticipated to occupy the largest market share in the overall antibody drug conjugates contract manufacturing market.

Market Share by Antibody Generation

Based on the antibody generation, the antibody market is segmented into second generation, third, fourth and next generation. Presently, the market is dominated by revenues generated from manufacturing of third generation antibodies, followed by fourth generation antibodies. This can be attributed to the fact that at present, nearly 40 percent of approved antibody drug conjugates and majority of the clinical stage antibody drug conjugates have third generation ADC component. This trend is unlikely to change in the near future.

Market Share by Antibody Origin

Based on the antibody origin, the antibody market is segmented into humanized, chimeric, murine and others. Currently, the market is primarily driven by ADCs utilizing human origin antibodies. This can be attributed to the fact that fully human origin antibodies have a low risk of generating immune reactions, as compared to murine or chimeric antibodies. It is worth mentioning that the market for chimeric origin ADCs is expected to grow at a relatively high CAGR, owing to their application in early stages of biotherapeutics research, as a more economical alternative to human or humanized antibodies.

Market Share by Type of Antibody Isotype

Based on the type of antibody isotype, the antibody market is segmented into IgG1, IgG4 and others. Presently, the market is dominated by IgG1 antibody isotype. This can be attributed to the fact that IgG1 is the most common isotype available in the serum. Further, it is highly active in eliciting an immune response via the Fc medicated effector function, which is the primary mode of action for tumor targeting therapies.

Market Share by Type of Payload

Based on the type of payload, the HPAPI / payload market is categorized into auristatin, camptothecin, DNA topoisomerase I inhibitor, maytansinoid and others. Presently, the market is dominated by camptothecin as an ADC payload. This can be primarily attributed to the fact that camptothecin-based therapies possess the potential to avoid peripheral neuropathy, which is the most common adverse event associated with auristatin-based therapies. Further, these payloads have higher tolerability, allowing for the administration of higher doses of ADCs, leading to an enhanced therapeutic effect.

It is worth highlighting that the market share for maytansinoid-based ADCs is likely to grow at a higher CAGR in the near future.

Market Share by Type of Linker

Based on the type of linker, the conjugation / linker market is categorized into Maleimide, SMCC, tetrapeptide-based linker, valine-citrulline and others. Presently, the market is dominated by Maleimide as an ADC linker and this trend is unlikely to change in the future as well. This can be attributed to the fact that Maleimide linkers are uncharged and lipophilic, which confers additional stability to the ADC therapeutic.

ADC Contract Manufacturing Market Share by Key Geographical Regions

This segment highlights the distribution of global ADC contract manufacturing market across various geographies, such as North America, Europe, and Asia-Pacific and rest of the world. According to the projections, the antibody drug conjugates contract manufacturing market in North America is likely to capture majority (46%) of the share, and this trend is unlikely to change in the future as well. It is worth highlighting that the market in Europe is expected to grow at a relatively higher CAGR (15%), during the period 2023-2035.

ADC Contract Manufacturing Market Key Insights

The market report features an extensive study of the current market landscape, market size and future opportunities for the companies involved in the ADC contract manufacturers, during the forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the ADC contract manufacturing market report are briefly discussed below.

Overall Market Landscape of ADC Contract Manufacturers: Majority of the Contract Manufacturers are Based in North America

The ADC contract manufacturing market landscape features the presence of 30 large, mid-sized and small companies. Over 45% of the companies were established before 2000, demonstrating extensive experience and expertise in the contract manufacturing industry. Examples of companies, established before 1980 (in alphabetical order) include Lonza, MilliporeSigma, Sartorius and Sterling Pharma Solutions. Further, it is worth highlighting that 50% of the ADC contract manufacturers are based in North America. Within Europe, Switzerland emerged as the hub of ADC contract manufacturers. Notably, 43% of the companies offer all types of manufacturing services related to ADCs. Moreover, industry stakeholders are actively undertaking expansion initiatives for their product / service portfolios to become one-stop shops for mitigating the challenges associated with technology transfer and scale-up.

Key Drivers for ADC Contract Manufacturing Market Growth: Increasing Demand for Antibody Drug Conjugates

The growth of the ADC contract manufacturing market can be attributed to the ever-increasing demand for advanced therapeutic modalities, such as antibody drug conjugates. The ADC therapeutics domain features a rich pipeline of commercialized ADCs. Additionally, a number of ADCs are being evaluated in clinical trials, owing to the highly selective and specific nature of antibody drug conjugates in targeting tumor cells. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain. The anticipated success of these drugs is likely to act as an impetus to the growth of overall ADC contract manufacturing market. It is important to note that ADCs are highly complex and unstable molecules, and require advanced technologies, expertise and manufacturing facilities for their production, which are available with contract manufacturers. Therefore, in recent years, an increased inclination of ADC developers towards outsourcing complex manufacturing operations has been observed, which is unlikely to change in the future.

Market Trend Analysis: Growing Interest in ADC Contract Manufacturing Market is Evident from the Rise in Partnership and Expansion Activity

Several stakeholders have been forging alliances with other industry / non-industry players in ADC contract manufacturing market for manufacturing antibody drug conjugates. It is worth highlighting that, since 2019, more than 30 partnerships have been inked in the industry. Further, the stakeholders are also acquiring other companies specializing in the manufacturing of various ADC components, in order to expand their existing capabilities and consolidate their product / service portfolio. In this context, in June 2023, Lonza acquired Synaffix in order to gain access to the company’s site specific linker technology platform and R&D capabilities.

Owing to the increasing outsourcing of ADC manufacturing process, several players in ADC contract manufacturing market have made significant investments in order to expand their existing facilities or establish new production plants. It is worth highlighting that over 35% of the expansions undertaken since 2019 have been inked in the last two years. Majority of the expansion instances reported in this domain were focused on expanding existing capabilities. Notably, ~91% of the expansions were being undertaken for offering ADC manufacturing services, followed by those being undertaken for offering analytical / development services for ADCs. Some examples of firms involved in the expansion initiatives include (in alphabetical order) Piramal Pharma Solutions and WuXi Biologics. It is interesting to note that more than 65% of the expansions were carried out in Europe, followed by those carried out in North America. As such, the ADC contract manufacturing companies in other regions are also expected to continue to carry out capacity expansions, driving the market growth for ADC contract manufacturing market.

ADC Contract Manufacturing Market Size: Antibody Segment to Hold the Largest Market Share

The global market for ADC contract manufacturing is estimated to be worth $1.79 billion in 2024. Owing to the increase in the outsourcing of ADC manufacturing, the market growth is expected to increase at a CAGR of ~13.8% over the forecast period. It is worth highlighting that, in terms of process component, antibody is expected to capture the majority of the shares of the ADC contract manufacturing market during the forecast period. This can be attributed to the fact that antibody production requires complex protein engineering and cellular approaches, which is a cost and time intensive process.

Regional Analysis: North America and Europe Emerged as the Hub of ADC Contract Manufacturing; Europe to be the Fastest Growing Market

Presently, North America and Europe capture more than 70% of the overall ADC contract manufacturing market size. In fact, in recent years, preference of ADC contract manufacturing in North America has witnessed a tremendous increase owing to the regulatory guidance and early approval for contract manufacturing applications by the Food and Drug Administration (FDA). It is worth highlighting that, in the coming years, owing to the anticipated increase in the establishment of ADC contract manufacturing facilities in Europe, this region is likely to grow at a higher CAGR as compared to other regions.

Key Players in ADC Contract Manufacturing Market

Examples of key ADC contract manufacturing organizations (CMOs) (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie Contract Manufacturing, Abzena, CARBOGEN AMCIS, Catalent Pharma Solutions, Cerbios-Pharma, Formosa Laboratories, GBI, Lonza, MabPlex, Millipore Sigma, Piramal Pharma Solutions, Sterling Pharma Solutions and WuXi Biologics. This market report includes an easily searchable excel database of all the ADC contract manufacturing organizations.

Recent Developments in the ADC Contract Manufacturing Market

Several recent developments have taken place in the field of ADC contract manufacturing. the analyst has outlined some of these recent initiatives below. These developments, even if they took place post the release of the market report, substantiate the overall trends that have been outlined in the ADC contract manufacturing market analysis.

  • In October 2023, Lonza entered into a manufacturing agreement with an unnamed partner in order to enhance commercial supplies of its antibody drug conjugates through the addition of two new bioconjugation suites at its manufacturing facility in Visp, Switzerland.
  • In October 2023, Lonza entered into an agreement with a major biopharmaceutical partner in order to support handling and filling of antibody drug conjugates for commercial supply through the addition of a new filling line at its facility in Stein, Switzerland.
  • In September 2023, WuXi Biologics inked a strategic deal with Mabwell Therapeutics to support and accelerate Mabwell’s ADC research, development and commercialization initiatives.

ADC Contract Manufacturing Market Report Coverage

The ADC contract manufacturing market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market research report includes:

  • A preface providing an introduction to the full report, ADC Contract Manufacturing Market (6th Edition), Industry Trends and Global Forecasts, till 2035.
  • An outline of the systematic research methodology adopted to conduct the study on ADC contract manufacturing market, providing insights on various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of the findings.
  • An overview of economic factors that impact the overall market outlook, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the key insights captured during the research, offering a high-level view of the current landscape of ADC contract manufacturing industry and its likely evolution in the short to mid and long term.
  • A general overview on the essential components of ADC therapeutics, the challenges associated with manufacturing of such therapies along with information on the rising trend of contract manufacturing in this segment of biopharmaceutical industry.
  • A detailed assessment of the overall market landscape of ADC contract manufacturers, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of ADC manufacturing service offered (antibody manufacturing, HPAPI and payload synthesis, linker manufacturing, conjugation and fill / finish services), type of additional service offered (proof-of-concept studies, process development and scale-up and analytical development), scale of operation (Preclinical, clinical and commercial) and location of manufacturing facility.
  • A detailed competitiveness analysis of ADC contract manufacturers, based on manufacturing strength (in terms of scale of operation and number of ADC manufacturing facilities), service strength (in terms of number of ADC services offered, number of additional services offered and location of ADC manufacturing facilities) and supplier strength (in terms of employee count and years of experience in this field).
  • Elaborate profiles of ADC contract manufacturers (shortlisted on the basis of competitiveness analysis). Each profile provides a brief overview of the company, its financial information (if available), manufacturing services portfolio (specific to antibody drug conjugates), location of production facilities, and an insightful recent development and future outlook.
  • A detailed analysis of the various expansion initiatives undertaken by ADC contract manufacturers, during the period 2019-2023, along with information on several relevant parameters, such as year of expansion, type of expansion, purpose of expansion (manufacturing, analytical / development and fill / finish), scale of operation (preclinical, clinical and commercial), location of expanded facility, type of facility and most active players (based on number of expansion initiatives).
  • An analysis of the recent partnerships inked between various ADC contract manufacturers, since 2019, based on several parameters, such as year of partnership, type of partnership (acquisitions, joint ventures, licensing agreements, manufacturing agreements, mergers, product development agreements, product development and manufacturing agreements, research agreements, technology integration agreements and others), purpose of agreement, scale of operation and most active players (in terms of number of partnerships). This section also highlights the regional distribution of partnership activity in this market.
  • A qualitative analysis highlighting the various factors that needs to be considered by ADC developers, while deciding whether to manufacture their respective products in-house or outsource the manufacturing operation to contract service providers.
  • A detailed discussion on various steps (antibody manufacturing, payload manufacturing, linker manufacturing, conjugation and fill / finish) involved in the manufacturing of ADCs, along with information on the cost requirements across each stage.
  • An estimate of the overall ADC manufacturing / bioconjugation capacity (in kilograms) of ADC contract manufacturers based on information provided by various stakeholders in the public domain. The analysis highlights the distribution of global capacity by company size (small, mid-sized and large), key geographical regions (North America, Europe and Asia-Pacific) and key players (in terms of highest bioconjugation capacity).
  • An overview of the current market landscape of ADCs, along with detailed analysis of the ADCs pipeline, based on several relevant parameters, such as status of development, target disease indication, therapeutic area, line of treatment, dosing frequency, type of therapy, target antigen, antibody isotype, payload / cytotoxin / warhead, type of payload and type of linker.
  • An in-depth analysis of completed and ongoing clinical studies of various antibody drug conjugates, based on several relevant parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor / collaborator, target population, study design, most active industry players, and non-industry players (in terms of number of trials) and key geographical regions.
  • An in-depth analysis of over 140 ADC therapy developers that are likely to partner with ADC contract manufacturers, based on several relevant parameters, such as developer strength (in terms of company size and its experience), pipeline maturity (in terms of number of drugs in pipeline, their stage of development and type of target indication) and manufacturing capabilities.
  • An informed estimate of the annual commercial and clinical demand for ADC therapeutics (in kilograms) based on, based on relevant parameters, such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
  • A detailed regional capability assessment framework comparing the key geographies, based on a number of parameters, including the number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC bioconjugation capacity, number of registered clinical trials and demand for ADCs in that particular geographical region.
  • A detailed assessment of the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments, plotted on a 2×2 matrix.
  • A detailed ADC contract manufacturing market forecast analysis in order to estimate the existing market size and future opportunity for ADC contract manufacturers over the next 12 years. Based on multiple parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market size during the forecast period 2024-2035.
  • Detailed projections of the current and future opportunity within the ADC contract manufacturing market across different stages of development, such as phase I, phase II, phase III and commercial.
  • Detailed projections of the current and future opportunity within antibody drug conjugates contract manufacturing market across different process components, such as antibody, HPAPI / cytotoxic payload, conjugation / linker and fill / finish.
  • Detailed projections of the current and future opportunity within the ADC contract manufacturing industry across different target indications, such as solid tumors, hematological tumors and others.
  • Detailed projections of the current and future opportunity within the market across different antibody generations, such as second, third, fourth and next generation.
  • Detailed projections of the current and future opportunity within the ADC contract manufacturing market across different antibody origins, such as humanized, chimeric, murine and others.
  • Detailed projections of the current and future opportunity within the antibody drug conjugates contract manufacturing market across different antibody isotypes, such as IgG1, IgG4 and others.
  • Detailed projections of the current and future opportunity within the ADC contract manufacturing market across different types of payloads, such as auristatin, camptothecin, DNA topoisomerase I inhibitor, maytansinoid and others.
  • Detailed projections of the current and future opportunity within the market across different types of linkers, such as Maleimide, SMCC, tetrapeptide-based linker, valine-citrulline and others.
  • Detailed projections of the current and future opportunity within the ADC contract manufacturing industry across key geographical regions, including North America, Europe, Asia-Pacific and rest of the world.
  • Detailed projections of the current and future opportunity within the commercial ADC contract manufacturing market, based on several relevant parameters such as type of component, target indications, type of generation, type of antibody origin, type of antibody isotype, type of payload, type of linker and key geographical regions.
  • Detailed projections of the current and future opportunity within the clinical ADC contract manufacturing market, based on several relevant parameters such as phase of development, type of component, target indications, type of antibody origin, type of antibody isotype, type of payload, type of linker and key geographical regions.
  • An in-depth analysis of the factors that can impact the growth of ADC contract manufacturing market. It also features identification of key drivers, potential restraints, emerging opportunities, and existing challenges.

One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential for the ADC contract manufacturing market, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period.

The ADC contract manufacturing market analysis also features the likely distribution of the current and forecasted opportunity within this market across various segments, such as stage of development (phase I, phase II, phase III and commercial), process component (antibody, HPAPI / cytotoxic payload, conjugation / linker and fill / finish), target indication (Solid Tumors, Hematological Tumors and others), antibody generation (second, third, fourth and next), antibody origin (humanized, chimeric, murine and others), antibody isotype (IgG1, IgG4 and others), type of payload (auristatin, camptothecin, DNA topoisomerase I inhibitor, maytansinoid and others), type of linker (Maleimide, SMCC, tetrapeptide-based linker, valine-citrulline and others), and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to the model, the analyst has provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the ADC contract manufacturing market. In addition, the research report features detailed transcripts of interviews held with the following industry stakeholders (arranged on the basis of designation):

  • Chief Executive Officer, Large Company, Italy and Technical Business Development Manager, Large Company, Italy
  • Chief Executive Officer and Founder, Small Company, UK
  • Chief Executive Officer and Co-Founder, Small Company, France
  • Former Chief Executive Officer, Large Company, US
  • Chief Commercial Officer, Mid-sized Company, Switzerland
  • Chief Business Officer, Small Company, Switzerland
  • Executive Director, Large Company, Japan and Chief Innovation Officer, Large Company, Japan
  • Director, Business Development, Small Company, Netherlands
  • Director Corporate Development, Mid-sized Company, US
  • Director, Business Development, Large Company, US and Former Group Product Manager, Large Company, US
  • Former Director of CDMO, Large Organization, France
  • Business Development Manager, Mid-sized Company, Switzerland
  • Former Head of Bioconjugates Commercial Development, Large Company, Switzerland
  • Former Site Head, Large Company, US
  • Associate Scientist, Large Company, US

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the ADC Contract Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. PREFACE
1.1. ADC Contract Manufacturers: Market Overview
1.2. Market Share Insights
1.3. Market Segmentation Overview
1.4. Key Market Insights
1.5. Report Coverage
1.6. Key Questions Answered
1.7. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Key Components of ADCs
5.2.1. Antibody
5.2.2. Cytotoxin (Payloads)
5.2.3. Linker
5.3. ADC Manufacturing
5.3.1. Key Steps
5.3.2. Technical Challenges
5.3.3. Need for Outsourcing
5.4. Challenges Associated with Supply Chain and Method Transfer
5.4.1. Growing Demand for One-Stop Shops and Integrated Service Providers
5.5. Selecting a CMO Partner
5.6. Future Perspective
6. ADC CONTRACT MANUFACTURERS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. ADC Contract Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of ADC Manufacturing Service Offered
6.2.5. Analysis by Type of Additional Service Offered
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Location of Manufacturing Facilities
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. MabPlex
7.2.1. Company Overview
7.2.2. ADC Related Services
7.2.3. Manufacturing Facilities
7.2.4. Recent Developments and Future Outlook
7.3. Lonza
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. ADC Related Services
7.3.4. Manufacturing Facilities
7.3.5. Recent Developments and Future Outlook
7.4. Abzena
7.4.1. Company Overview
7.4.2. ADC Related Services
7.4.3. Manufacturing Facilities
7.4.4. Recent Developments and Future Outlook
7.5. GBI
7.5.1. Company Overview
7.5.2. ADC Related Services
7.5.3. Manufacturing Facilities
7.5.4. Recent Developments and Future Outlook
7.6. CARBOGEN AMCIS
7.6.1. Company Overview
7.6.2. ADC Related Services
7.6.3. Manufacturing Facilities
7.6.4. Recent Developments and Future Outlook
7.7. Millipore Sigma
7.7.1. Company Overview
7.7.2. ADC Related Offerings
7.7.3. Manufacturing Facilities
7.7.4. Recent Developments and Future Outlook
7.8. WuXi Biologics
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. ADC Related Services
7.8.4. Manufacturing Facilities
7.8.5. Recent Developments and Future Outlook
7.9. Catalent Pharma Solutions
7.9.1. Company Overview
7.9.2. Financial Information
7.9.3. ADC Related Services
7.9.4. Manufacturing Facilities
7.9.5. Recent Developments and Future Outlook
7.10. Cerbios-Pharma
7.10.1. Company Overview
7.10.2. ADC Related Services
7.10.3. Manufacturing Facilities
7.10.4. Recent Developments and Future Outlook
7.11. Formosa Laboratories
7.11.1. Company Overview
7.11.2. ADC Related Services
7.11.3. Manufacturing Facilities
7.11.4. Recent Developments and Future Outlook
7.12. Sterling Pharma Solutions
7.12.1. Company Overview
7.12.2. ADC Related Services
7.12.3. Manufacturing Facilities
7.12.4. Recent Developments and Future Outlook
7.13. Piramal Pharma Solutions
7.13.1. Company Overview
7.13.2. ADC Related Services
7.13.3. Manufacturing Facilities
7.13.4. Recent Developments and Future Outlook
7.14. AbbVie Contract Manufacturing
7.14.1. Company Overview
7.14.2. ADC Related Services
7.14.3. Manufacturing Facilities
7.14.4. Recent Developments and Future Outlook
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. ADC Contract Manufacturers: Company Competitiveness Analysis
8.4.1. ADC Contract Manufacturers based in North America (Peer Group I)
8.4.2. ADC Contract Manufacturers based in Europe (Peer Group II)
8.4.3. ADC Contract Manufacturers based in Asia-Pacific (Peer Group III)
8.5. Capability Benchmarking of Top ADC Contract Manufacturers
9. ADC CONTRACT MANUFACTURERS: RECENT EXPANSIONS
9.1. Chapter Overview
9.2. ADC Contract Manufacturers: Recent Expansions
9.2.1. Analysis by Year of Expansion
9.2.2. Analysis by Type of Expansion
9.2.3. Analysis by Purpose of Expansion
9.2.4. Analysis by Scale of Operation
9.2.5. Analysis by Location of Expanded Facility
9.2.6. Most Active Players: Analysis by Number of Expansions
10. ADC CONTRACT MANUFACTURERS: PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. ADC Contract Manufacturers: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Purpose of Partnership
10.3.4. Analysis by Scale of Operation
10.3.5. Most Active Players: Analysis by Number of Partnerships
10.3.6. Analysis by Geography
10.3.6.1. Intercontinental and Intracontinental Agreements
10.3.6.2. Local and International Agreements
11. MAKE VERSUS BUY DECISION MAKING
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.2.1. Scenario 1
11.2.2. Scenario 2
11.2.3. Scenario 3
11.2.4. Scenario 4
11.3. Concluding Remarks
12. VALUE CHAIN ANALYSIS
12.1. Chapter Overview
12.2. ADC Development Value Chain
12.3. Cost Distribution across the Value Chain
12.3.1. Cost Associated with Antibody Manufacturing
12.3.2. Cost Associated with Payload and Linker Manufacturing
12.3.3. Cost Associated with Conjugation
12.3.4. Cost Associated with Fill / Finish
13. ADC MANUFACTURING: CAPACITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. ADC Manufacturing: Global Installed Capacity
13.3.1. Analysis by Company Size
13.3.2. Analysis by Location of Headquarters
13.3.3. Analysis by Location of Manufacturing Facilities
13.3.3.1 Analysis by Region
13.3.3.2. Analysis by Country
13.3.4. Analysis by Key Players
14. ADC THERAPEUTICS: MARKET OVERVIEW
14.1. Chapter Overview
14.2. Antibody Drug Conjugates: Therapies Pipeline
14.2.1. Analysis by Status of Development
14.2.2. Analysis by Target Disease Indication
14.2.3. Analysis by Therapeutic Area
14.2.4. Analysis by Line of Treatment
14.2.5. Analysis by Dosing Frequency
14.2.6. Analysis by Type of Therapy
14.2.7. Analysis by Target Antigen
14.2.8. Analysis by Antibody Isotype
14.2.9. Analysis by Payload / Cytotoxin / Warhead
14.2.10. Analysis by Type of Payload
14.2.11. Analysis by Linker
14.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
14.3. Antibody Drug Conjugates: Therapies to Watch
14.4. Concluding Remarks
15. CLINICAL TRIAL ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Antibody Drug Conjugates: Clinical Trial Analysis
15.3.1. Analysis by Trial Registration Year
15.3.2. Analysis by Trial Status
15.3.3. Analysis of Enrolled Patient Population by Trial Status
15.3.4. Analysis by Trial Registration Year and Trial Status
15.3.5. Analysis of Enrolled Patient Population by Trial Registration Year
15.3.6. Analysis by Trial Phase
15.3.7. Analysis of Enrolled Patient Population by Trial Phase
15.3.8. Analysis by Type of Sponsor / Collaborator
15.3.9. Analysis by Target Population
15.3.10. Analysis by Study Design
15.3.11. Most Active Industry Players: Analysis by Number of Trials
15.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
15.3.13. Analysis of Clinical Trials by Geography
15.3.14. Analysis of Enrolled Patient Population by Geography
16. LIKELY PARTNER ANALYSIS
16.1. Chapter Overview
16.2. Scoring Criteria and Key Assumptions
16.3. Scope and Methodology
16.4. Potential Strategic Partners based in North America
16.4.1. Most Likely Partners
16.4.2. Likely Partners
16.4.3. Least Likely Partners
16.5. Potential Strategic Partners based in Europe
16.5.1. Most Likely Partners
16.5.2. Likely Partners
16.5.3. Least Likely Partners
16.6. Potential Strategic Partners based in Asia-Pacific and Rest of the World
16.6.1. Most Likely Partners
16.6.2. Likely Partners
16.6.3. Least Likely Partners
17. ADC THERAPEUTICS: DEMAND ANALYSIS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. ADC Therapeutics: Global Annual Demand
17.3.1. ADC Therapeutics: Annual Commercial Demand
17.3.1.1. Analysis by Target Indication
17.3.1.2. Analysis by Antibody Origin
17.3.1.3. Analysis by Antibody Isotype
17.3.1.4. Analysis by Type of Payload
17.3.1.5. Analysis by Type of Linker
17.3.1.6 Analysis by Key Geographical Regions
17.3.2. ADC Therapeutics: Annual Clinical Demand
17.3.2.1. Analysis by Phase of Development
17.3.2.2. Analysis by Target Indication
17.3.2.3. Analysis by Antibody Origin
17.3.2.4. Analysis by Antibody Isotype
17.3.2.5. Analysis by Type of Payload
17.3.2.6. Analysis by Type of Linker
17.3.2.7. Analysis by Key Geographical Regions
18. REGIONAL CAPABILITY ANALYSIS
18.1. Chapter Overview
18.2. Assumptions and Key Parameters
18.3. ADC Contract Manufacturing Capabilities in North America
18.4. ADC Contract Manufacturing Capabilities in Europe
18.5. ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World
19. ATTRACTIVENESS COMPETETIVENESS MATRIX
19.1. Chapter Overview
19.2. AC Matrix: Overview
19.2.1. Strong Business Segments
19.2.2. Average Business Segments
19.2.3. Weak Business Segments
19.3. AC Matrix: Analytical Methodology
19.4. AC Matrix: Overall ADC Contract Manufacturing Market Scenario
19.4.1. AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
19.4.2. AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions
20. ADC CONTRACT MANUFACTURING MARKET
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Global ADC Therapeutics Market, Historical Trends and Forecasted Estimates, till 2035
20.4. Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035
20.4.1. Scenario Analysis
20.5. Key Market Segmentations
21. ADC CONTRACT MANUFACTURING MARKET, BY STAGE OF DEVELOPMENT
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035
21.3.1. Phase I: Forecasted Estimates, till 2035
21.3.2. Phase II: Forecasted Estimates, till 2035
21.3.3. Phase III: Forecasted Estimates, till 2035
21.3.4. Commercial: Forecasted Estimates, till 2035
21.4. Data Triangulation and Validation
22. ADC CONTRACT MANUFACTURING MARKET, BY PROCESS COMPONENT
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035
22.3.1. Antibody: Forecasted Estimates, till 2035
22.3.2. HPAPI / Cytotoxic Payload: Forecasted Estimates, till 2035
22.3.3. Conjugation / Linker: Forecasted Estimates, till 2035
22.3.4. Fill / Finish: Forecasted Estimates, till 2035
22.4. Data Triangulation and Validation
23. ADC CONTRACT MANUFACTURING MARKET, BY TARGET INDICATION
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035
23.3.1. Solid Tumors: Forecasted Estimates, till 2035
23.3.2. Hematological Tumors: Forecasted Estimates, till 2035
23.3.3. Others: Forecasted Estimates, till 2035
23.4. Data Triangulation and Validation
24. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY GENERATION
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035
24.3.1. Second Generation: Forecasted Estimates, till 2035
24.3.2. Third Generation: Forecasted Estimates, till 2035
24.3.3. Fourth Generation: Forecasted Estimates, till 2035
24.3.4. Next Generation: Forecasted Estimates, till 2035
24.4. Data Triangulation and Validation
25. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ORIGIN
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035
25.3.1. Human Origin: Forecasted Estimates, till 2035
25.3.2. Chimeric Origin: Forecasted Estimates, till 2035
25.3.3. Murine Origin: Forecasted Estimates, till 2035
25.3.4. Others: Forecasted Estimates, till 2035
25.4. Data Triangulation and Validation
26. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ISOTYPE
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2029 and 2035
26.3.1. IgG1: Forecasted Estimates, till 2035
26.3.2. IgG4: Forecasted Estimates, till 2035
26.3.3. Others: Forecasted Estimates, till 2035
26.4. Data Triangulation and Validation
27. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF PAYLOAD
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2029 and 2035
27.3.1.Camptothecin: Forecasted Estimates, till 2035
27.3.2. Maytansinoid: Forecasted Estimates, till 2035
27.3.3. Auristatin: Forecasted Estimates, till 2035
27.3.4. DNA topoisomerase I inhibitor: Forecasted Estimates, till 2035
27.3.5. Others: Forecasted Estimates, till 2035
27.4. Data Triangulation and Validation
28. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF LINKER
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2029 and 2035
28.3.1. Maleimide: Forecasted Estimates, till 2035
28.3.2. SMCC: Forecasted Estimates, till 2035
28.3.3. Tetrapeptide-based linker: Forecasted Estimates, till 2035
28.3.4. Valine-citrulline: Forecasted Estimates, till 2035
28.3.5. Others: Forecasted Estimates, till 2035
28.4. Data Triangulation and Validation
29. ADC CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2029 and 2035
29.3.1. North America: Forecasted Estimates, till 2035
29.3.2. Europe: Forecasted Estimates, till 2035
29.3.3. Asia-Pacific and Rest of the World: Forecasted Estimates, till 2035
29.4. Data Triangulation and Validation
30. COMMERCIAL ADC CONTRACT MANUFACTURING MARKET
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
30.3.1. Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
30.3.2. Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
30.3.3. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035
30.3.4. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
30.3.5. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
30.3.6. Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
30.3.7. Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
30.3.8. Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035
30.4. Data Triangulation and Validation
31. CLINICAL ADC CONTRACT MANUFACTURING MARKET
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
31.3.1. Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035
31.3.2. Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
31.3.3. Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
31.3.4. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
31.3.5. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
31.3.6. Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
31.3.7. Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
31.3.8. Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035
31.4. Data Triangulation and Validation
32. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
32.1. Chapter Overview
32.2. Market Drivers
32.3. Market Restraints
32.4. Market Opportunities
32.5. Market Challenges
32.6. Conclusion
33. CONCLUDING REMARKS
34. INTERVIEW TRANSCRIPTS
34.1. Chapter Overview
34.2. Company A
34.2.1. Company Snapshot
34.2.2. Interview Transcript: Chief Executive Officer and Technical Business Development Manager
34.3. Company B
34.3.1. Company Snapshot
34.3.2. Interview Transcript: Chief Executive Officer and Founder
34.4. Company C
34.4.1. Company Snapshot
34.4.2. Interview Transcript: Former Chief Executive Officer
34.5. Company D
34.5.1. Company Snapshot
34.5.2. Interview Transcript: Chief Executive Officer and Co-Founder
34.6. Company E
34.6.1. Company Snapshot
34.6.2. Interview Transcript: Chief Commercial Officer
34.7. Company F
34.7.1. Company Snapshot
34.7.2. Interview Transcript: Chief Business Officer
34.8. Company G
34.8.1. Company Snapshot
34.8.2. Interview Transcript: Executive Director and Chief Innovation Officer
34.9. Company H
34.9.1. Company Snapshot
34.9.2. Interview Transcript: Director, Business Development
34.10. Company I
34.10.1. Company Snapshot
34.10.2. Interview Transcript: Former Director of CDMO
34.11. Company J
34.11.1. Company Snapshot
34.11.2. Interview Transcript: Director Corporate Development
34.12. Company K
34.12.1. Company Snapshot
34.12.2. Interview Transcript: Business Development Manager
34.13. Company L
34.13.1. Company Snapshot
34.13.2. Interview Transcript: Director, Business Development and Former Group Product Manager
34.14. Company M
34.14.1. Company Snapshot
34.14.2. Interview Transcript: Former Head of Bioconjugates Commercial Development
34.15. Company N
34.15.1. Company Snapshot
34.15.2. Interview Transcript: Former Site Head
34.16. Company O
34.16.1. Company Snapshot
34.16.2. Interview Transcript: Associate General Manager
34.17. Interview Transcript: Director, Business Development, Leading CMO
34.18. Interview Transcript: Chief Executive Officer, Leading CMO
35. APPENDIX I: TABULATED DATA36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Recent Expansions
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Capacity Analysis
Figure 4.5 Executive Summary: Clinical Trial Analysis
Figure 4.6 Executive Summary: Demand Analysis
Figure 4.7 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Key Components of an ADC
Figure 5.2 ADC Manufacturing Steps
Figure 5.3 Key Parameters while Selecting a CMO Partner
Figure 6.1 ADC Contract Manufacturers: Distribution by Year of Establishment
Figure 6.2 ADC Contract Manufacturers: Distribution by Company Size
Figure 6.3 ADC Contract Manufacturers: Distribution by Location of Headquarters(Region)
Figure 6.4 ADC Contract Manufacturers: Distribution by Location of Headquarters(Country)
Figure 6.5 ADC Contract Manufacturers: Distribution by Company Size and Location of Headquarters
Figure 6.6 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
Figure 6.7 ADC Contract Manufacturers: Distribution by Location of Headquarters and ADC Manufacturing Service Offered
Figure 6.8 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
Figure 6.9 ADC Contract Manufacturers: Distribution by Scale of Operation
Figure 6.10 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered and Scale of Operation
Figure 6.11 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
Figure 7.1 Lonza: Annual Revenues, FY 2019-H1 FY 2023 (CHF Billion)
Figure 7.2 WuXi Biologics: Annual Revenues, FY 2019-H1 FY 2023 (RMB Billion)
Figure 7.3 Catalent Pharma Solutions: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
Figure 8.1 Company Competitiveness Analysis: ADC Contract Manufacturers based in North America
Figure 8.2 Company Competitiveness Analysis: ADC Contract Manufacturers based in Europe
Figure 8.3 Company Competitiveness Analysis: ADC Contract Manufacturers based in Asia-Pacific
Figure 8.4 Capability Benchmarking: Distribution of Top 9 Players (Wind Rose Representation)
Figure 9.1 Recent Expansions: Cumulative Year-wise Trend, 2013-2023
Figure 9.2 Recent Expansions: Distribution by Type of Expansion
Figure 9.3 Recent Expansions: Distribution by Purpose of Expansion
Figure 9.4 Recent Expansions: Distribution by Year of Expansion and Purpose of Expansion
Figure 9.5 Recent Expansions: Distribution by Scale of Operation
Figure 9.6 Recent Expansions: Distribution by Location of Expanded Facility
Figure 9.7 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Figure 9.8 Most Active Players: Distribution by Number of Expansions
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2023
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 10.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 10.6 Most Active Players: Distribution by Number of Partnership Instances
Figure 10.7 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 10.8 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 11.1 Make versus Buy Decision Making Framework
Figure 11.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 12.1 Value Chain Analysis: ADC Development Overview
Figure 12.2 Value Chain Analysis: ADC Contract Manufacturing Overview
Figure 12.3 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing
Figure 12.4 Value Chain Analysis: Distribution by Cost
Figure 12.5 Costs Associated with Antibody Manufacturing
Figure 12.6 Costs Associated with Payload and Linker Manufacturing
Figure 12.7 Costs Associated with Conjugation
Figure 12.8 Costs Associated with Fill / Finish
Figure 13.1 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
Figure 13.2 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
Figure 13.3 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Region)
Figure 13.4 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country)
Figure 13.5 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
Figure 14.1 Antibody Drug Conjugates: Distribution by Status of Development
Figure 14.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
Figure 14.3 Antibody Drug Conjugates: Distribution by Therapeutic Area
Figure 14.4 Antibody Drug Conjugates: Distribution by Line of Treatment
Figure 14.5 Antibody Drug Conjugates: Distribution by Dosing Frequency
Figure 14.6 Antibody Drug Conjugates: Distribution by Type of Therapy
Figure 14.7 Antibody Drug Conjugates: Distribution by Target Antigen
Figure 14.8 Antibody Drug Conjugates: Distribution by Antibody Isotype
Figure 14.9 Antibody Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Figure 14.10 Antibody Drug Conjugates: Distribution by Type of Payload
Figure 14.11 Antibody Drug Conjugates: Distribution by Linker
Figure 14.12 Antibody Drug Conjugates: Distribution by Type of Linker
Figure 15.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2016-2023
Figure 15.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 15.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
Figure 15.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2023
Figure 15.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2016-2023
Figure 15.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 15.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 15.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 15.9 Clinical Trial Analysis: Distribution by Target Population
Figure 15.10 Clinical Trial Analysis: Distribution by Study Design
Figure 15.11 Most Active Industry Players: Distribution by Number of Trials
Figure 15.12 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 15.13 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 15.14 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 17.1 Global Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.2 Global Demand for ADC Therapeutics: Distribution by Stage of Development, 2023-2035 (in kg)
Figure 17.3 Global Commercial Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.4 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Figure 17.5 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2023-2035 (in kg)
Figure 17.6 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Figure 17.7 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Figure 17.8 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Figure 17.9 Global Commercial Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Figure 17.10 Global Clinical Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.11 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2023-2035 (in kg)
Figure 17.12 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Figure 17.13 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
Figure 17.14 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Figure 17.15 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Figure 17.16 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Figure 17.17 Global Clinical Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Figure 18.1 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in North America
Figure 18.2 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Europe
Figure 18.3 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World
Figure 19.1 AC Matrix: Pictorial Representation
Figure 19.2 AC Matrix: Overall ADC Contract Manufacturing Market Scenario, 2023-2028 and 2029-2035
Figure 19.3 AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
Figure 19.4 AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions
Figure 20.1 Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035
Figure 20.2 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Base Scenario (USD Million)
Figure 20.3 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Million)
Figure 20.4 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Million)
Figure 21.1 Global ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035 (USD Million)
Figure 21.2 ADC Contract Manufacturing Market for Phase I ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.3 ADC Contract Manufacturing Market for Phase II ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.4 ADC Contract Manufacturing Market for Phase III ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.5 ADC Contract Manufacturing Market for Commercial ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 22.1 Global ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035 (USD Million)
Figure 22.2 ADC Contract Manufacturing Market for Antibody, Forecasted Estimates, till 2035 (USD Million)
Figure 22.3 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 22.4 ADC Contract Manufacturing Market for Conjugation / Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 22.5 ADC Contract Manufacturing Market for Fill / Finish, Forecasted Estimates, till 2035 (USD Million)
Figure 23.1 Global ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035 (USD Million)
Figure 23.2 ADC Contract Manufacturing Market for Solid Tumors, Forecasted Estimates, till 2035 (USD Million)
Figure 23.3 ADC Contract Manufacturing Market for Hematological Tumors, Forecasted Estimates, till 2035 (USD Million)
Figure 23.4 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 24.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035 (USD Million)
Figure 24.2 ADC Contract Manufacturing Market for Second Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.3 ADC Contract Manufacturing Market for Third Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.4 ADC Contract Manufacturing Market for Fourth Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.5 ADC Contract Manufacturing Market for Next Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 25.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035 (USD Million)
Figure 25.2 ADC Contract Manufacturing Market for Humanized Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.3 ADC Contract Manufacturing Market for Chimeric Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.4 ADC Contract Manufacturing Market for Murine Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.5 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 26.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2028 and 2035 (USD Million)
Figure 26.2 ADC Contract Manufacturing Market for IgG1, Forecasted Estimates, till 2035 (USD Million)
Figure 26.3 ADC Contract Manufacturing Market for IgG4, Forecasted Estimates, till 2035 (USD Million)
Figure 26.4 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 27.1 Global ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2028 and 2035 (USD Million)
Figure 27.2 ADC Contract Manufacturing Market for Camptothecin, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.3 ADC Contract Manufacturing Market for Maytansinoid, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.4 ADC Contract Manufacturing Market for Auristatin, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.5 ADC Contract Manufacturing Market for DNA Topoisomerase I Inhibitor, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.6 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 28.1 Global ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2028 and 2035 (USD Million)
Figure 28.2 ADC Contract Manufacturing Market for Maleimide, Forecasted Estimates, till 2035 (USD Million)
Figure 28.3 ADC Contract Manufacturing Market for SMCC, Forecasted Estimates, till 2035 (USD Million)
Figure 28.4 ADC Contract Manufacturing Market for Tetrapeptide-based linker, Forecasted Estimates, till 2035 (USD Million)
Figure 28.5 ADC Contract Manufacturing Market for Valine-citrulline, Forecasted Estimates, till 2035 (USD Million)
Figure 28.6 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 29.1 Global ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
Figure 29.2 ADC Contract Manufacturing Market in North America, Forecasted Estimates, till 2035 (USD Million)
Figure 29.3 ADC Contract Manufacturing Market in Europe, Forecasted Estimates, till 2035 (USD Million)
Figure 29.4 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Forecasted Estimates, till 2035 (USD Million)
Figure 30.1 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Figure 30.2 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Figure 30.3 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Figure 30.4 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 30.5 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 30.6 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Figure 30.7 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 30.8 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 30.9 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
Figure 31.1 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Figure 31.2 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Million)
Figure 31.3 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Figure 31.4 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Figure 31.5 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 31.6 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Figure 31.7 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 31.8 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 31.9 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
Figure 33.1 Concluding Remarks: Market Landscape
Figure 33.2 Concluding Remarks: Recent Expansions
Figure 33.3 Concluding Remarks: Partnerships and Collaborations
Figure 33.4 Concluding Remarks: Clinical Trial Analysis
Figure 33.5 Concluding Remarks: Likely Partner Analysis
Figure 33.6 Concluding Remarks: Capacity Analysis
Figure 33.7 Concluding Remarks: Demand Analysis
Figure 33.8 Concluding Remarks: Market Sizing and Opportunity Analysis
LIST OF TABLES
Table 5.1 Common Cytotoxins used for the Production of ADCs
Table 5.2 Safebridge Categorization / OEL Bands for Highly Potent / Cytotoxic Compounds
Table 6.1 ADC Contract Manufacturers: Information on Year of Establishment, Company Size, Location of Headquarters and Type of Manufacturer
Table 6.2 ADC Contract Manufacturers: Information on Type of ADC Manufacturing Service Offered
Table 6.3 ADC Contract Manufacturers: Information on Type of Additional Service Offered and Scale of Operation
Table 6.4 ADC Contract Manufacturers: Information on Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
Table 7.1 List of Companies Profiled
Table 7.2 MabPlex: Company Overview
Table 7.3 MabPlex: ADC Related Services
Table 7.4 MabPlex: Information on Manufacturing Facilities
Table 7.5 Lonza: Company Overview
Table 7.6 Lonza: ADC Related Services
Table 7.7 Lonza: Information on Manufacturing Facilities
Table 7.8 Lonza: Recent Developments and Future Outlook
Table 7.9 Abzena: Company Overview
Table 7.10 Abzena: ADC Related Services
Table 7.11 Abzena: Information on Manufacturing Facilities
Table 7.12 Abzena: Recent Developments and Future Outlook
Table 7.13 GBI: Company Overview
Table 7.14 GBI: ADC Related Services
Table 7.15 GBI: Information on Manufacturing Facilities
Table 7.16 CARBOGEN AMCIS: Company Overview
Table 7.17 CARBOGEN AMCIS: ADC Related Services
Table 7.18 CARBOGEN AMCIS: Information on Manufacturing Facilities
Table 7.19 CARBOGEN AMCIS: Recent Developments and Future Outlook
Table 7.20 Millipore Sigma: Company Overview
Table 7.21 Millipore Sigma: ADC Related Services
Table 7.22 Millipore Sigma: Information on Manufacturing Facilities
Table 7.23 WuXi Biologics: Company Overview
Table 7.24 WuXi Biologics: ADC Related Services
Table 7.25 WuXi Biologics: Information on Manufacturing Facilities
Table 7.26 WuXi Biologics: Recent Developments and Future Outlook
Table 7.27 Catalent Pharma Solutions: Company Overview
Table 7.28 Catalent Pharma Solutions: ADC Related Services
Table 7.29 Catalent Pharma Solutions: Information on Manufacturing Facilities
Table 7.30 Catalent Pharma Solutions: Recent Developments and Future Outlook
Table 7.31 Cerbios-Pharma: Company Overview
Table 7.32 Cerbios-Pharma: ADC Related Services
Table 7.33 Cerbios-Pharma: Information on Manufacturing Facilities
Table 7.34 Cerbios-Pharma: Recent Developments and Future Outlook
Table 7.35 Formosa Laboratories: Company Overview
Table 7.36 Formosa Laboratories: ADC Related Services
Table 7.37 Formosa Laboratories: Information on Manufacturing Facilities
Table 7.38 Sterling Pharma Solutions: Company Overview
Table 7.39 Sterling Pharma Solutions: ADC Related Services
Table 7.40 Sterling Pharma Solutions: Information on Manufacturing Facilities
Table 7.41 Sterling Pharma Solutions: Recent Developments and Future Outlook
Table 7.42 Piramal Pharma Solutions: Company Overview
Table 7.43 Piramal Pharma Solutions: ADC Related Services
Table 7.44 Piramal Pharma Solutions: Information on Manufacturing Facilities
Table 7.45 Piramal Pharma Solutions: Recent Developments and Future Outlook
Table 7.46 AbbVie Contract Manufacturing: Company Overview
Table 7.47 AbbVie Contract Manufacturing: ADC Related Services
Table 7.48 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
Table 9.1 ADC Contract Manufacturers: Information on Month and Year of Expansion, Type of Expansion, Purpose of Expansion and Scale of Operation, 2019-2023
Table 9.2 ADC Contract Manufacturers: Information on Location of Expanded Facility and Type of Facility
Table 10.1 ADC Contract Manufacturers: Information on Year of Partnership, Type of Partnership, Purpose of Partnership and Scale of Operation, 2019-2023
Table 10.2 ADC Contract Manufacturers: Information on Type of Agreement (Country and Continent)
Table 12.1 ADC Components: Information on Cost of Cytotoxins
Table 12.2 ADC Components: Information on Cost of Linkers
Table 13.1 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Yield)
Table 13.2 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Average Capacity)
Table 13.3 Global Installed ADC Manufacturing Capacity: Information on Total Capacity based on Company Size
Table 14.1 Antibody Drug Conjugates: Information on Drug Candidates, Developers, Status of Development, Target Disease Indication and Therapeutic Area
Table 14.2 Antibody Drug Conjugates to Watch: Information on Drug Candidates, Developer, Status of Development, Target Disease Indication and Therapeutic Area
Table 16.1 Most Likely Partners based in North America
Table 16.2 Likely Partners based in North America
Table 16.3 Least Likely Partners based in North America
Table 16.4 Most Likely Partners based in Europe
Table 16.5 Likely Partners based in Europe
Table 16.6 Least Likely Partners based in Europe
Table 16.7 Most Likely Partners based in Asia-Pacific and Rest of the World
Table 16.8 Likely Partners based in Asia-Pacific and Rest of the World
Table 16.9 Least Likely Partners based in Asia-Pacific and Rest of the World
Table 17.1 List of Late Stage ADCs
Table 34.1 BSP Pharmaceuticals: Key Highlights
Table 34.2 Oxford BioTherapeutics: Key Highlights
Table 34.3 Abzena: Key Highlights
Table 34.4 Syndivia: Key Highlights
Table 34.5 Cerbios-Pharma: Key Highlights
Table 34.6 NBE-Therapeutics: Key Highlights
Table 34.7 Eisai: Key Highlights
Table 34.8 Synaffix: Key Highlights
Table 34.9 Pierre Fabre: Key Highlights
Table 34.10 Goodwin Biotechnology: Key Highlights
Table 34.11 Cerbios-Pharma: Key Highlights
Table 34.12 Catalent Pharma Solutions: Key Highlights
Table 34.13 Lonza: Key Highlights
Table 34.14 Piramal Pharma Solutions: Key Highlights
Table 34.15 Ajinomoto Bio-Pharma Services: Key Highlights
Table 35.1 ADC Contract Manufacturers: Distribution by Year of Establishment
Table 35.2 ADC Contract Manufacturers: Distribution by Company Size
Table 35.3 ADC Contract Manufacturers: Distribution by Location of Headquarters (Region)
Table 35.4 ADC Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 35.5 ADC Contract Manufacturers: Distribution by Company Size and Location of Headquarters
Table 35.6 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
Table 35.7 ADC Contract Manufacturers: Distribution by Location of Headquarters and ADC Manufacturing Service Offered
Table 35.8 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
Table 35.9 ADC Contract Manufacturers: Distribution by Scale of Operation
Table 35.10 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered and Scale of Operation
Table 35.11 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
Table 35.12 Lonza: Annual Revenues, FY 2019-H1 FY 2023 (CHF Billion)
Table 35.13 WuXi Biologics: Annual Revenues, FY 2019-H1 FY 2023 (RMB Billion)
Table 35.14 Catalent Pharma Solutions: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
Table 35.15 Recent Expansions: Cumulative Year-wise Trend, 2013-2023
Table 35.16 Recent Expansions: Distribution by Type of Expansion
Table 35.17 Recent Expansions: Distribution by Purpose of Expansion
Table 35.18 Recent Expansions: Distribution by Year of Expansion and Purpose of Expansion
Table 35.19 Recent Expansions: Distribution by Scale of Operation
Table 35.20 Recent Expansions: Distribution by Location of Expanded Facility
Table 35.21 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Table 35.22 Most Active Players: Distribution by Number of Expansions
Table 35.23 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2023
Table 35.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 35.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 35.26 Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 35.27 Partnerships and Collaborations: Distribution by Scale of Operation
Table 35.28 Most Active Players: Distribution by Number of Partnership Instances
Table 35.29 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 35.30 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 35.31 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
Table 35.32 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
Table 35.33 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Region)
Table 35.34 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country)
Table 35.35 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
Table 35.36 Antibody Drug Conjugates: Distribution by Status of Development
Table 35.37 Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 35.38 Antibody Drug Conjugates: Distribution by Therapeutic Area
Table 35.39 Antibody Drug Conjugates: Distribution by Line of Treatment
Table 35.40 Antibody Drug Conjugates: Distribution by Dosing Frequency
Table 35.41 Antibody Drug Conjugates: Distribution by Type of Therapy
Table 35.42 Antibody Drug Conjugates: Distribution by Target Antigen
Table 35.43 Antibody Drug Conjugates: Distribution by Antibody Isotype
Table 35.44 Antibody Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Table 35.45 Antibody Drug Conjugates: Distribution by Type of Payload
Table 35.46 Antibody Drug Conjugates: Distribution by Linker
Table 35.47 Antibody Drug Conjugates: Distribution by Type of Linker
Table 35.48 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2016-2023
Table 35.49 Clinical Trial Analysis: Distribution by Trial Status
Table 35.50 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
Table 35.51 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2023
Table 35.52 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2016-2023
Table 35.53 Clinical Trial Analysis: Distribution by Trial Phase
Table 35.54 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 35.55 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 35.56 Clinical Trial Analysis: Distribution by Target Population
Table 35.57 Clinical Trial Analysis: Distribution by Study Design
Table 35.58 Most Active Industry Players: Distribution by Number of Trials
Table 35.59 Most Active Non-Industry Players: Distribution by Number of Trials
Table 35.60 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 35.61 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 35.62 Global Demand for ADC Therapeutics, 2023-2035 (in kg)
Table 35.63 Global Demand for ADC Therapeutics: Distribution by Stage of Development, 2023-2035 (in kg)
Table 35.64 Global Commercial Demand for ADC Therapeutics, 2023-2035 (in kg)
Table 35.65 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Table 35.66 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2023-2035 (in kg)
Table 35.67 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Table 35.68 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Table 35.69 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Table 35.70 Global Commercial Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Table 35.71 Global Clinical Demand for ADC Therapeutics, 2023-2035 (in kg)
Table 35.72 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2023-2035 (in kg)
Table 35.73 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Table 35.74 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
Table 35.75 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Table 35.76 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Table 35.77 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Table 35.78 Global Clinical Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Table 35.79 Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035 (USD Billion)
Table 35.80 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Billion)
Table 35.81 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Billion)
Table 35.82 Global ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035 (USD Billion)
Table 35.83 ADC Contract Manufacturing Market for Phase I ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.84 ADC Contract Manufacturing Market for Phase II ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.85 ADC Contract Manufacturing Market for Phase III ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.86 ADC Contract Manufacturing Market for Commercial ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.87 Global ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035 (USD Billion)
Table 35.88 ADC Contract Manufacturing Market for Antibody, Forecasted Estimates, till 2035 (USD Billion)
Table 35.89 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payload, Forecasted Estimates, till 2035 (USD Billion)
Table 35.90 ADC Contract Manufacturing Market for Conjugation / Linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.91 ADC Contract Manufacturing Market for Fill / Finish, Forecasted Estimates, till 2035 (USD Billion)
Table 35.92 Global ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035 (USD Billion)
Table 35.93 ADC Contract Manufacturing Market for Solid Tumors, Forecasted Estimates, till 2035 (USD Billion)
Table 35.94 ADC Contract Manufacturing Market for Hematological Tumors, Forecasted Estimates, till 2035 (USD Billion)
Table 35.95 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.96 Global ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035 (USD Billion)
Table 35.97 ADC Contract Manufacturing Market for Second Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.98 ADC Contract Manufacturing Market for Third Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.99 ADC Contract Manufacturing Market for Fourth Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.100 ADC Contract Manufacturing Market for Next Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.101 Global ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035 (USD Billion)
Table 35.102 ADC Contract Manufacturing Market for Human Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.103 ADC Contract Manufacturing Market for Chimeric Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.104 ADC Contract Manufacturing Market for Murine Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.105 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.106 Global ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2028 and 2035 (USD Billion)
Table 35.107 ADC Contract Manufacturing Market for IgG1, Forecasted Estimates, till 2035 (USD Billion)
Table 35.108 ADC Contract Manufacturing Market for IgG4, Forecasted Estimates, till 2035 (USD Billion)
Table 35.109 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.110 Global ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2028 and 2035 (USD Billion)
Table 35.111 ADC Contract Manufacturing Market for Camptothecin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.112 ADC Contract Manufacturing Market for Maytansinoid, Forecasted Estimates, till 2035 (USD Billion)
Table 35.113 ADC Contract Manufacturing Market for Auristatin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.114 ADC Contract Manufacturing Market for DNA Topoisomerase I Inhibitor, Forecasted Estimates, till 2035 (USD Billion)
Table 35.115 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.116 Global ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2028 and 2035 (USD Billion)
Table 35.117 ADC Contract Manufacturing Market for Maleimide, Forecasted Estimates, till 2035 (USD Billion)
Table 35.118 ADC Contract Manufacturing Market for SMCC, Forecasted Estimates, till 2035 (USD Billion)
Table 35.119 ADC Contract Manufacturing Market for Tetrapeptide-based linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.120 ADC Contract Manufacturing Market for Valine-citrulline, Forecasted Estimates, till 2035 (USD Billion)
Table 35.121 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.122 Global ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Billion)
Table 35.123 ADC Contract Manufacturing Market in North America, Forecasted Estimates, till 2035 (USD Billion)
Table 35.124 ADC Contract Manufacturing Market in Europe, Forecasted Estimates, till 2035 (USD Billion)
Table 35.125 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Forecasted Estimates, till 2035 (USD Billion)
Table 35.126 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Billion)
Table 35.127 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Billion)
Table 35.128 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Billion)
Table 35.129 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.130 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.131 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Billion)
Table 35.132 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Billion)
Table 35.133 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.134 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Billion)
Table 35.135 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Billion)
Table 35.136 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Billion)
Table 35.137 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Billion)
Table 35.138 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Billion)
Table 35.139 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.140 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Billion)
Table 35.141 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Billion)
Table 35.142 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.143 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie
  • AbbVie Contract Manufacturing
  • ABL Bio
  • AbTis
  • Abzena
  • ACES Pharma
  • ADC Biotechnology (Acquired by Sterling Pharma Solutions)
  • ADC Therapeutics
  • Adcentrx Therapeutics
  • AIMEDBIO
  • Ajinomoto
  • Ajinomoto Bio-Pharma Services
  • Almac
  • Alphamab Oncology
  • ALSA Ventures
  • Alteogen
  • Ambrx
  • Amgen
  • Angiex
  • Araris Biotech
  • Asana BioSciences
  • Astellas Pharma
  • AstraZeneca
  • ATB Therapeutics
  • Atreca
  • Avipep Therapeutics
  • Axplora
  • Bayer
  • BeiGene
  • Bicycle Therapeutics
  • Bio-Synthesis
  • Bio-Thera Solutions
  • BioAtla
  • Biocytogen
  • BioMed Valley Discoveries
  • BiOneCure Therapeutics
  • Bioqube Ventures
  • Biosion
  • BiVictriX Therapeutics
  • BOC Sciences
  • Bolt Biotherapeutics
  • Boostimmune
  • Bristol-Myers Squibb
  • BSP Pharmaceuticals
  • Byondis
  • Cambrex
  • CARBOGEN AMCIS
  • Catalent Pharma Solutions
  • Celltrion
  • Centrose
  • Cerbios-Pharma
  • ChemPartner
  • Corbus Pharmaceuticals
  • Creative Biolabs
  • Cristal Therapeutics
  • CSPC Pharmaceutical
  • CStone Pharmaceuticals
  • CureMeta
  • CytomX Therapeutics
  • Daiichi Sankyo
  • Dalton Pharma Services
  • Dantari
  • Debiopharm
  • Diatheva
  • Duality Biologics
  • Eisai
  • Elevation Oncology
  • EMD Serono
  • Emergence Therapeutics
  • Exelixis
  • Farmabios
  • Formosa Laboratories
  • Formosa Pharmaceuticals
  • Fortis Therapeutics
  • Fosun Pharma
  • GBI
  • Genentech
  • GeneQuantum Healthcare
  • Genmab
  • Genor Biopharma
  • Gilead Sciences
  • Glycotope
  • GSK
  • GTP Bioways
  • Hangzhou Adcoris BioPharma
  • Hangzhou DAC Biotech
  • Harbour BioMed
  • Heidelberg Pharma
  • Hisun Pharmaceuticals
  • Hummingbird Bioscience
  • Iconic Therapeutics
  • Iksuda Therapeutics
  • ImmuneOncia Therapeutics
  • ImmunoBiochem
  • ImmunoGen
  • Immunome
  • Innovent Biologics
  • IntoCell
  • iProgen Biotech
  • KLUS Pharma (Subsidiary of Kelun-Biotech)
  • Kodiak Sciences
  • LaNova Medicines
  • LegoChem Biosciences
  • Lepu Biopharma
  • Levena Biopharma
  • Light Chain Bioscience
  • Lonza
  • Luzsana Biotechnology
  • Mablink Bioscience
  • MabPlex
  • Mabwell (Shanghai) Bioscience
  • Mabwell Therapeutics
  • MacroGenics
  • Magenta Therapeutics
  • McSAF
  • MediaPharma
  • MediLink Therapeutics
  • Megalith Pharmaceuticals
  • Menarini
  • Merck
  • Mersana Therapeutics
  • MilliporeSigma
  • Mitsubishi Tanabe Pharma
  • MuseChem
  • Mythic Therapeutics
  • NanoValent Pharmaceuticals
  • Navrogen
  • NBE-Therapeutics
  • Nordic Nanovector
  • NovaRock Biotherapeutics
  • Novartis
  • Novasep
  • NovoCodex Biopharmaceuticals
  • OBI Pharma
  • OGD2 Pharma
  • Oncolinx
  • Oncomatryx Biopharma
  • OnCusp Therapeutics
  • Orano Med
  • Oxford BioTherapeutics
  • Paul Scherrer Institute
  • Peak Bio
  • Perseus Proteomics
  • Pfizer
  • Pheon Therapeutics
  • Pierre Fabre
  • PinotBio
  • Piramal Pharma Solutions
  • ProfoundBio
  • Pyxis Oncology
  • Rakuten Medical
  • Recipharm
  • Regeneron
  • RemeGen
  • Sanofi
  • Sartorius
  • Schengen Pharma
  • Seagen
  • Shanghai Fudan Zhangjiang Biopharmaceutical
  • Shanghai Hansoh Biomedical
  • Shanghai Pharmaceuticals
  • Singzyme
  • Sorrento Therapeutics
  • SOTIO Biotech
  • Sterling Pharma Solutions
  • Sutro Biopharma
  • Synaffix
  • Syngene
  • SystImmune
  • Takeda
  • Takeda Oncology
  • Tanabe Research Laboratories
  • Targinta (Subsidiary of Xintela)
  • Toray Industries
  • TOT BIOPHARM
  • TRIO Pharmaceuticals
  • Triphase Accelerator
  • Tubulis
  • UCB
  • University Medical Center Groningen
  • Vincerx Pharma
  • WuXi Biologics
  • WuXi STA (A subsidiary of WuXi AppTec)
  • Y-Biologics
  • Zhejiang Teruisi Pharmaceutical
  • Zydus Lifesciences
  • Zymework

Methodology

 

 

Loading
LOADING...

Table Information